Skip to main content
. Author manuscript; available in PMC: 2018 Apr 30.
Published in final edited form as: Int J Cancer. 2016 Jan 28;138(10):2487–2498. doi: 10.1002/ijc.29989

Figure 6.

Figure 6

Combination treatment with GW788388 and IL-23 aiming to sustain Th17 cell levels increases spleen cell production of the inflammatory mediators IL-17 and TNF-α, the stimulatory mediators IL-2, IFN-γ and RANTES, and the inhibitory mediator IL-10. Starting from Week 6 of 4NQO administration, when premalignant oral lesions were detectable on the tongue, mice were initiated on treatment with diluent, GW788388, IL-23 or both GW788388 and IL-23. After 2 months of these treatments, spleens were collected and cultured on anti-CD3 for 3 days. Supernatants were collected and used for measurement of the inflammatory mediators IL-17, TNF-α and IL-6 (a); stimulatory mediators IL-2, IFN-γ and RANTES (b); and inhibitory mediators, TGF-β, IL-4 and IL-10 (c). * = p <0.05, ** = p <0.01, *** = p <0.001.